替米沙坦片在高血压治疗中应用及临床效果初步评价.docVIP

替米沙坦片在高血压治疗中应用及临床效果初步评价 　　[摘要] 目的 分析替米沙坦片在高血压治疗中的应用及临床效果和安全性。方法 方便选取于2016年5―11月该院诊治的82例原发性高血压者分为观察、对照两组，每组41例。对照组使用贝那普利片治疗，观察组使用替米沙坦片治疗，分析药物安全性，逆转左心室肥厚效果和不良反应。结果 对照组患者治疗有效率为 80.49%，观察组为 95.12%（P0.05）。对照组患者治疗后LVMI为（138.25±15.29），观察组为（162.52±12.28）（P0.05）。治疗后对照组A/E为（0.95±0.43），观察组为（1.11±0.45），（P0.05）。治疗后对照组IVST以及LVPWT分别为（11.99±2.52）mm和（10.36±2.36）mm，观察组为（9.84±2.62）mm和（9.25±2.03）mm（P0.05）。 结论 对于原发性高血压者，使用替米沙坦治疗，安全性强，不良反应少，可有效逆转左心室肥厚，有效性高，值得进一步推广使用。 　　[关键词] 替米沙坦；原发性高血压；左心室肥厚 　　[中图分类号] R544 [文献标识码] A [文章编号] 1674-0742（2017）08（a）-0129-03 　　[Abstracts] Objective This paper tries to analyze the application of telmisartan tablets in the treatment of hypertension and its clinical effect and safety. Methods 82 cases of primary hypertension were from May to November 2016 were convenient selected and divided into the observation and the control group， with 41 cases in each group. The control group adopted benazepril tablets treatment， the observation group was treated with telmisartan tablets， and the drug safety， reverse left ventricular hypertrophy effects and adverse reactions were analyzed. Results The treatment effective rate of the control group was 80.49%， that of the observation group was 95.12%（P0.05）. The LVMI in the control group was（138.25±15.29），and that of the observation group was（162.52±12.28）（P0.05）. The A/E of the control group after treatment was（0.95±0.43），that of the observation group was（1.11±0.45）（P0.05）. The IVST and LVPWT in the control group after treatment was respectively （11.99±2.52）mm and （10.36±2.36）mm， and those of the observation group was （9.84±2.62）mm and （9.25±2.03）mm（P0.05）. Conclusion The use of telmisartan treatment for the primary hypertension is safe， with fewer adverse reactions and high effectiveness， which can effectively reverse left ventricular hypertrophy， and it is worth further promotion. 　　[Key words] Telmisartan； Primary hypertension； Left ventricular hypertrophy 　　高血压为临床常见慢性终身性疾病。最近几年，随着人们生活质量的不断提升，该疾病的发生率也呈现出了逐年增多的趋势，严重威